Биология ва тиббиёт муаммолари 2025, №4 (163)
Subject of the article
GENETIC PREDISPOSITION TO ANTIPLATELET RESISTANCE IN UZBEK PATIENTS WITH CORONARY ARTERY DISEASE (34-38)
Authors
Alyavi Anis Lutfullayevich, Khodjanova Shakhnoza Iskandarovna
Institution
1 - Republican Specialized Scientific and Practical Medical Center for Therapy and Medical Rehabilitation, Republic of Uzbekistan, Tashkent; 2 - Tashkent State Medical University, Republic of Uzbekistan, Tashkent
Abstract
The purpose of the work: to ascertain the prevalence and composition of genetic variables that influence a person's susceptibility to developing antiplatelet resistance in Uzbek patients suffering from coronary heart disease. Materials and methods: There were 75 Uzbek participants with coronary heart disease and 60 healthy participants in the study. A two-channel laser analyzer called the Alat-2 Biol was used to assess platelet function. The AGGR program was then used for computer processing. To identify the mutation of the platelet ADP receptor P2RY12 and the polymorphism of the α-subunit GP1BA, genetic tests were conducted. Results of the study: According to the results of the study of platelet aggregation activity, 17 (22.6% and the average degree of platelet aggregation with 5.0 mmol of ADP was 73.2%) pa-tients with no reaction to aspirin were identified.The control group had significantly lower mutant allele frequencies for the studied polymorphisms (17.4% in the CP1BA (Thr145Met) gene and 28.7% in the H1/H2 (P2RY12) gene) compared to the study group (46.8% and 62.6%, respectively, p<0.05). The analysis of the frequency of polymorphisms revealed significant excess frequencies of mutant CP1BA alleles in the homozygous form (=1.94, respectively, p<0.001) in patients with antiplatelet resistance. Conclusions: Therefore, correlations with the H2 genotype of the polymorphism of the ADP P2Y12 receptor gene were found in Uzbek nationals with coronary artery disease who also had antiplatelet resistance.
Key words
resistance to antiplatelet agents, coronary heart disease, platelet aggregation, genes.
Literature
1. Graziansky N.A. Antiplatelet therapy in coronary heart disease. Some challenges and achievements. Atherothrombosis 2011; 1 (4): 2-52. 2. Sirotkina O.V. Molecular genetic mechanisms of platelet activation and sensitivity to antiplatelet drugs in patients with cardiovascular diseases. Biomedical and social safety issues in emergency situations 2010; 4(1): 69-76. 3. Khodzhanova Sh. I. Determination of aspirin resistance in patients with chronic coronary syndrome //Botkin readings. - 2020. – pp. 295-296. 4.Khodzhanova Sh. I., Alyavi A. L. The role of polymorphisms of some genes related to the function of platelet hemostasis in antiplatelet resistance //Science and innovation in the education system. – 2024. – Vol. 3. – no. 13. pp. 86-87. 5.Khodzhanova Sh. I., Alyavi A. L., Kadyrova S. A. Platelet aggregation in patients with coronary heart disease with obesity : dis. – All-Russian Therapeutic Congress with international participation Botkin readings 20-21 April 2023 Pp. 296. 6.Bhatt DL, Grosser T, Dong JF, et al. Enteric Coating and Aspirin Nonresponsiveness in Patients With Type 2 Diabetes Mellitus. J Am Coll Cardiol. 2017;69(6):603-612. 7.Christiansen M, Grove EL, Hvas AM. Primary Prevention of Cardiovascular Events with Aspirin: Toward More Harm than Benefit-A Systematic Review and Meta-Analysis. Semin Thromb Hemost. 2019;45(5):478-489. 8.Elliott MA. The Aspirin-NSAID Interaction: More Data, But a Lack of Clarity Remains. J Am Coll Cardiol. 2018; 71(16):1752-1754. 9.Gori AM, Marcucci R, Migliorini A, et al. Inci-dence and clinical impact of dual nonresponsiveness to aspirin and clopidogrel in patients with drug-eluting stents. JACC 2008 Aug 26; 52(9): 734-9. 10.Goodman T, Ferro A, Sharma P. Pharmacogenetics of aspirin resistance: a comprehensive systematic review. Br J Clin Pharmacol. 2008;66(2):222-232. 11.Ferguson AD, Dokainish H, Lakkis N. Aspirin and clopidogrel response variability: review of the published literature. Tex Heart Inst J 2008; 35(3): 313-20. 12.Floyd CN, Ferro A. Mechanisms of aspirin re-sistance. Pharmacol Ther. 2014;141(1):69-78. 13.Floyd C.N., Ferro A. The PlA1/A2 polymorphism of glycoprotein IIIa in relation to efficacy of antiplatelet drugs: a systematic review and meta-analysis. Br J Clin Pharmacol. 2014 Mar;77(3):446-57. 14.Poorani R, Bhatt AN, Dwarakanath BS, et al. COX-2, aspirin and metabolism of arachidonic, eicosapentaenoic and docosahexaenoic acids and their physiological and clinical significance. Eur J Pharmacol. 2016;785:116-132. 15.Rocca B, Fox KAA, Ajjan RA, et al. Antithrombotic therapy and body mass: an expert position paper of the ESC Working Group on Thrombosis. Eur Heart J. 2018;39(19):1672-1686f. 16.Iskandarovna, Khodjanova Shakhnoza, and Alyavi Anis Lutfullayevich. "Clinical and Laboratory Features of Coronary Heart Disease in Patients with Aspirin Resistance." American Journal of Medicine and Medical Sciences 11.3 (2021). 17.Khodjanova S. I. Yurak ishemik kasalligi mavjud bemorlarda atsetilsalitsil kislotaning antiagregant va yallig'lanishga qarshi xususiyatlari //journal of biomedicine and practice. – 2021. – Т. 6. – №. 1. 18.Mukarram O., Akhtar N., Junaid A., Mohyuddin A. A study into the genetic basis of aspirin resistance in Pakistani patients with coronary artery disease. Pak J Pharm Sci. 2016 Jul;29(4):1177-82. 19.Weng Z., Li X., Li Y., Lin J., Peng F., Niu W. The association of four common polymorphisms from four candidate genes (COX-1, COX-2, ITGA2B, ITGA2) with aspirin insensitivity: a meta-analysis. PLoS One. 2013 Nov 14;8(11):e78093. 20.Xu Z.H., Jiao J.R, Yang R., Luo B.Y., Wang X.F., Wu F. Aspirin resistance: clinical significance and genetic polymorphism. J Int Med Res. 2012;40(1):282-292. 21.Zhao Z., Li X., Sun S., Mei S., Ma N., Miao Z., Zhao M., Peng S. Impact of genetic polymorphisms related to clopidogrel or acetylsalicylic acid pharmacology on clinical outcome in Chinese patients with symptomatic extracranial or intracranial stenosis. Eur J Clin Pharmacol. 2016 Oct; 72(10): 1195-1204.